Organon & Co (OGN) - Total Liabilities
Based on the latest financial reports, Organon & Co (OGN) has total liabilities worth $-906.00 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash flow conversion of Organon & Co to assess how effectively this company generates cash.
Organon & Co - Total Liabilities Trend (2018–2025)
This chart illustrates how Organon & Co's total liabilities have evolved over time, based on quarterly financial data. Check OGN cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Organon & Co Competitors by Total Liabilities
The table below lists competitors of Organon & Co ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ruentex Development Co Ltd
TW:9945
|
Taiwan | NT$86.41 Billion |
|
Compania Cervecerias Unidas SA
SN:CCU
|
Chile | CL$2.03 Trillion |
|
Hunan Zhongke Electric
SHE:300035
|
China | CN¥8.56 Billion |
|
Chow Tai Seng Jewellery Co Ltd
SHE:002867
|
China | CN¥1.94 Billion |
|
Russel Metals Inc.
TO:RUS
|
Canada | CA$1.10 Billion |
|
Elekta AB (publ)
ST:EKTA-B
|
Sweden | Skr19.74 Billion |
|
AUB Group Ltd
AU:AUB
|
Australia | AU$2.66 Billion |
|
Shandong Dawn Polymer Co Ltd
SHE:002838
|
China | CN¥3.17 Billion |
Liability Composition Analysis (2018–2025)
This chart breaks down Organon & Co's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Organon & Co (OGN) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | N/A | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.00 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | N/A | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Organon & Co's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Organon & Co (2018–2025)
The table below shows the annual total liabilities of Organon & Co from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $-906.00 Million | -107.17% |
| 2024-12-31 | $12.63 Billion | +4.13% |
| 2023-12-31 | $12.13 Billion | +2.37% |
| 2022-12-31 | $11.85 Billion | -2.81% |
| 2021-12-31 | $12.19 Billion | +163.66% |
| 2020-12-31 | $4.62 Billion | +31.60% |
| 2019-12-31 | $3.51 Billion | -15.27% |
| 2018-12-31 | $4.15 Billion | -- |
About Organon & Co
Organon & Co. develops and delivers health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a… Read more